Compare KeyCorp (KEY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Tango Therapeutics Inc. — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: KeyCorp is far larger — about 5.7× Tango Therapeutics Inc.'s market cap, and KeyCorp pays a 4.12% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Tango Therapeutics Inc. for 0 Days on average.
| KEY | TNGX | |
|---|---|---|
Market Cap | $21.25B | $3.74B |
Volume | 17,676,934 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $23.99 | $32.90 |
52-Week Low | $16.78 | $7.50 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $2.76B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.91, down 0.9% on the day, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Analyst consensus remains strongly bullish with a $25.00 price target, representing 25% upside potential. Recent corporate developments include leadership appointments and a maintained dividend payout.
KEY presents a compelling value opportunity with attractive valuation metrics (P/E 11.64, P/B 1.23) and improving profitability (26.72% net margin). However, technical indicators signal near-term weakness, and the stock faces headwinds from interest rate sensitivity and competitive pressure on dividends. The disconnect between strong fundamentals and bearish technicals creates potential for recovery if earnings momentum continues.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
